Vascular Biogenics Ltd. (VBLT)

0.02 1.75
NASDAQ : Health Technology
Prev Close 1.14
Open 1.15
Day Low/High 1.15 / 1.18
52 Wk Low/High 0.60 / 1.90
Volume 4.97K
Avg Volume 46.90K
Exchange NASDAQ
Shares Outstanding 35.85M
Market Cap 42.31M
EPS -0.60
P/E Ratio 1.59
Div & Yield N.A. (N.A)

Latest News

VBL Therapeutics Announces Second Quarter 2017 Financial Results

VBL Therapeutics Announces Second Quarter 2017 Financial Results

Conference Call and Webcast at 8:30am Eastern Time Today

Vascular Biogenics is Now Oversold (VBLT)

Vascular Biogenics is Now Oversold (VBLT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

VBL Therapeutics Provides Update On Long-Term Survival In Phase 2 Trials Of Patients With Multiple Tumor Types

Data to be Presented at 2017 BIO International Convention in San Diego, CA

VBL Therapeutics Announces Appointment Of Dr. Corinne Epperly As U.S. Chief Operating Officer

Industry leader with extensive oncology experience joins company as VB-111 advances toward registration

VBL Therapeutics To Present At Upcoming June Conferences

Update on Long term Survival of VB-111 Treated Patients to be Presented at BIO on June 20

TheStreet Quant Rating: D- (Sell)